Heart Failure

AI-enabled remote cardiac monitoring offers continuous data on heart activity, allowing for the early detection of arrhythmias, optimized treatment timing, and improved sleep-related heart health management.

New insights into heart failure risks in Native American communities are highlighting the need to address social determinants of health.

Women's health extends beyond reproductive health, yet much of the research in women's health focuses on these "below the belt" health issues, despite data showing that women disproportionately suffer from certain health conditions, such as heart failure.

Investigators compare the impact of semaglutide for preserved ejection fraction and reduced ejection fraction, which both have different causes and responses to treatment.

Joseph Saseen offers valuable insights into the implications of the added performance and quality measures for patients and health care providers.

Craig Beavers discusses significance of the 2024 update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure.

Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.

Tirzepatide demonstrates statistically significant improvements in adult patients who have heart failure with preserved ejection fraction and obesity.

Investigators compared the criteria for eligibility in the VICTORIA trial with guideline and label criterion, finding a wider than expected population with heart failure were eligible for vericiguat therapy.

Consumer-wearable devices can monitor treatment response and provide continuous health data for patients with heart disease and atrial fibrillation.

The RECTIFIER framework was able to screen patients with heart failure more accurately and with a cheaper cost than traditional screening methods.

This narrative review dispels the long-held belief that reduction in salt intake leads to better health outcomes in patients with heart failure.

Semaglutide significantly improved heart failure symptoms and quality of life through weight loss and direct effects on heart tissue.

Semaglutide was found to have effects on glycemia, inflammation, and heart failure outcomes in sub analyses.

Small steps can accumulate and have a big impact on patients’ lives

The finding did not reach statistical significance in the primary composite endpoint.

Investigators reported a low incidence of adverse events after simultaneous vaccination against seasonal influenza and respiratory syncytial virus.

Although newly approved, there is some debate regarding the benefits and populations in which sotagliflozin will be the most effective.

Findings showed that pharmacists frequently communicated with patients to implement complex plans.

Initiating and optimizing heart failure guideline-directed medical therapy is critical to the comprehensive management of heart failure.

Experts sheds light on gaps in gender and use of referrals, health literacy, and medication access in the treatment of patients with heart failure.

Cardioprotective antihyperglycemic agents are underutilized for inpatient care in heart failure patients. Lack of use can lead to preventable patient deaths and hospital readmissions.

The investigators identified 4 prognostic factors with high predictive ability and supported by moderate to high strength evidence beyond what is already available for cardiovascular disease.

Leg compression therapy was associated with decreased brain natriuretic peptide levels without any adverse events for patients with stable chronic heart failure.

Investigators determined the effectiveness of behavioral activation psychotherapy versus antidepressant medication management for inpatients with heart failure and depression.